You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Should We Evaluate Cardiac Biomarkers Differently in Transgender Patients?

To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

  1. You are a member of the healthcare team, caring for a couple comprising of a 25-year-old transgender woman and a 29-year-old cisgender man. The man presented with chest pain and palpitations to the emergency department 3 days ago and was evaluated with high-sensitivity cardiac troponin (hs-cTn). In general, how would his hs-cTn levels compare with those of a cisgender woman of the same age?
    They would be modestly higher
    They would be modestly lower
    They would be similar
    They would be lower if the man was underweight
  2. The 25-year-old transgender woman has a history of viral myocarditis and is followed with serial measurements of NT-proBNP. She takes estrogen regularly. On the basis of the results of the current study by Greene and colleagues, what should the healthcare team consider regarding her NT-proBNP values?
    She should be assessed with a scale for normal applicable to cisgender men
    She should be assessed with a scale for normal applicable to cisgender women
    The chronic use of estrogen obviates the value of NT-proBNP
    The cutline for a high NT-proBNP level should be increased by 40%